CD38 and neoplasm: In order to determine whether antibodies bound to CD38 could influence DTT-mediated denaturation of CD38, we incubated CD38-expressing tumor cells with 5 mM DTT and NAD+, in the presence or absence of daratumumab or hcAb MU1067 and analyzed the reaction products by HPLC (Figure 6).